Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

Haematologica

Volumn 95, Issue 7, 2010, Pages 1098-1105

  Blum, William ^a   Phelps, Mitch A ^b   Klisovic, Rebecca B ^a   Rozewski, Darlene M ^b   Ni, Wenjun ^b   Albanese, Katie A ^b   Rovin, Brad ^b   Kefauver, Cheryl ^b   Devine, Steven M ^a   Lucas, David M ^a   Johnson, Amy ^a   Schaaf, Larry J ^a   Byrd, John C ^a   Marcucci, Guido ^a   Grever, Michael R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute leukemia; Flavopiridol; Pharmacokinetics; Refractory; Relapsed

Indexed keywords

FLAVOPIRIDOL; HYDROXYUREA; FLAVONOID; PIPERIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HEART EJECTION FRACTION; HEMODIALYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY FAILURE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LUNG TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; QT PROLONGATION; SIDE EFFECT; TUMOR LYSIS SYNDROME; ACUTE DISEASE; DRUG ADMINISTRATION; FEMALE; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHARMACOKINETICS; PROCEDURES; SALVAGE THERAPY; TOXICITY; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHARMACOKINETICS; PIPERIDINES; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954499305     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.017103     Document Type: Article

References (45)

1. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces Gl arrest with inhibition of cyclin-depend-ent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996;56(13):2973-8.
2. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 1994;201(2):589-95.
3. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H,Myers C,et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992;84(22):1736-40.
4. Naik RG, Kattige SL, Bhat SV,et al. An anti-inflamatory cum immunomodulatory Tetrahedron 1988;44:2081-6.
5. Chao SH, Price DH., Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 2001;276(34):31793-9.
6. Chao SH,Fujinaga K, Marion JE,Taube R, Sausville EA,Senderowicz AM, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem. 2000;275 (37):28345-8.
7. de Azevedo WF, Jr Canduri F,da Silveira NJ,Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun. 2002;293 (1):566-71.
8. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001;2(10):RESEARCH0041.
9. Gojo I, Zhang B, Fenton RG,. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8(ll):3527-38.
10. Kitada S, Zapata JM, Andreeff M, Reed JC, Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate anti-apoptosis proteins inB-cell chronic lymphocytic leukemia. Blood. 2000;96(2):393-7.
11. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, et al. Flavopiridol down-regulates antiapop-totic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003;63(l):93-9.
12. Hussain SR, Lucas DM, Johnson AJ, LinTS, Bakaletz AP, Dang VX,et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood. 2008;lll(6):3190-9.
13. Arguello F, Alexander M, Sterry JA, Tudor G,Smith EM, Kalavar NT, et al. Flavopiridol induces apoptosis of normal lymphoid cells causes immunosuppres-sion and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood. 1998;91(7):2482-90.
14. Thomas JP, Tutsch KD, Cleary JF, Bailey HH. Arzoomanian R, Alberti, D et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol. 2002; 50(6):465-72.
15. Senderowicz AM, Headlee D, Stinson SF, Lush RM Kalil N Villalba L et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16(9):2986-99.
16. Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol.2002;20(8):2157-70.
17. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005;29(11): 1253-7.
18. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol. 2002;20(19):4074-82.
19. Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G, et al. Flavopiridol-related proinflammatory syndrome is associated with induction of inter-leukin-6. Clin Cancer Res. 2003;9(2):562-70.
20. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol. 2003;14(8): 1270-3.
21. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol. 2001;19(7):1985-92.
22. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D,et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000; 18(2):371-5.
23. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res. 2001;7(6):1590-9.
24. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11(11):4176-81.
25. Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, et al. Flavopiridol in untreated or relapsed man-de-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21(9):1740-5.
26. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res. 2003;9(1):307-15.
27. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, et al. Phase I and Pharmacokinetic Study of Flavopiridol followed by l-{beta}-D-Arabinofuranosyl-cytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias. Clin Cancer Res. 2005;11(23):8403-12.
28. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007;13(15 Pt 1):4467-73.
29. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109(2):399-404.
30. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113(12):2637-45.
31. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
32. Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, et al. Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;868(l-2):110-5.
33. Ramirez J, Iyer L, Journault K, Belanger P, Innocent F, Ratain MJ, et al. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res. 2002;19(5):588-94.
34. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100(13):4325-36.
35. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93(ll):3983-93.
36. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000;6(9):3400-5.
37. Rudek MA Bauer KS Jr Lush RM 3rd Stinson SF, Senderowicz AM Headlee DJ et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother. 2003;37(10):1369-74.
38. Jager W, Zembsch B, Wolschann P, Pittenauer E, Senderowicz AM, Sausville EA, et al. Metabolism of the anticancer drug flavopiridol a new inhibitor of cyclin dependent kinases, in rat liver. Life Sd. 1998;62(20):1861-73.
39. Jager W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. Biliary excretion of flavopiridol and its glu-curonides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2). Life Sci. 2003;73(22):2841-54.
40. Jager W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. Int J Clin Pharmacol Ther. 2003;41(12):610-1.
41. Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, et al. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anticancer Drugs. 2003;14(2):125-35.
42. Tan AR, Yang X, Berman A, Zhai S, SparreboomA Parr AL etal. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(15):5038-47.
43. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I Ernst DS, Walsh W, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs. 2004;22(3):315-22.
44. Bolanos-Meade J, Karp JE, Guo C, Sarkodee-Adoo CB, Rapoport AP, Tidwell ML, et al. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cyto-sine arabinoside, idarubidn and etoposide. Leuk Res. 2003;27(4):313-21.
45. Geller RB, Burke PJ, Karp JE, Humphrey RL, Braine HG, Tucker RW, et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood. 1989;74(5):1499-506.